Dopamine agonists
- bromocriptine (Parlodel)
- cabergoline (Cabaser)
- pergolide (Celance)
- pramipexole (Mirapexin)
- ropinirole (Requip)
- rotigotine (Neupro)
Advantages
Control of symptoms during the day may last longer than is usually the case with Sinemet or Madopar and where this applies, people with Parkinson's may be less prone to long-term side effects such as the 'on/off' effect and dyskinesias.Disadvantages
Dopamine agonists require careful introduction, with the dose gradually increased until a satisfactory response is achieved. At the lowest doses, people may experience a lack of effect or, paradoxically, a temporary worsening of their Parkinson's, but usually benefits appear as the dosage is increased. Dopamine agonists are usually introduced very gradually and slowly increased. This is to minimise the risk of symptomatic postural hypotension and/or sustained low blood pressure. When used alone, dopamine agonists are generally considered to be less effective than the standard forms of levodopa (Sinemet or Madopar). Some people with Parkinson's are unable to continue taking dopamine agonists because of side effects, which can include:- nausea
- sickness
- confusion
- hallucinations
- ankle swelling
- dizziness often related to low blood pressure
- existing dyskinesias may become more troublesome
- drowsiness, sometimes be severe.
Dopamine agonists - subcutaneous
- Apomorphine (APO-go)
Advantages
It acts very quickly and reliably so that people who need to be active at specific times can continue with their normal activities. It can bring great relief to people who are experiencing extreme variations in mobility and prolonged 'off' periods.Disadvantages
Apomorphine can only help those people with Parkinson's who show a response to Sinemet or Madopar. It can cause nausea and therefore another drug called domperidone (Motilium), which acts specifically against nausea and sickness, has to be taken in addition, at least while apomorphine is being introduced.(published with permission in writing from:http://www.parkinsons.org.uk)


